Skip to main content

Table 1 Characteristics of the LCH patients at the time of initiation of vinblastine

From: Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study

Characteristic

N = 35

Age, years, median, [IQR]

33 [28–42]

Male sex, n (%)

23 (66%)

Smoker, n (%)

18 (53%)

Ex-smoker

9 (27%)

Non-smoker

7 (20%)

LCH localizations, n (%)

 Bone

27 (77%)

 Lung

17 (49%)

 Pituitary stalk

14 (40%)

  Diabetes insipidus

14 (40%)

  Anterior hypophysis dysfunctiona

9 (26%)

 Skin

10 (29%)

 Peripheral lymph nodes

5 (14%)

 Mucosa

3 (9%)

 Liverb

4 (11%)

 CNSc

3 (9%)

 Gut

1 (3%)

 Hematologic involvementb,d

1 (3%)

 Spleend

1 (3%)

 Soft tissue

1 (3%)

MS LCH

28 (80%)

 RO (−)

24 (69%)

 RO (+)

4 (11%)

SS bone LCH

7 (20%)

 UFB with risk bone lesions

4 (11%)

 MFB

3 (9%)

  1. IQR interquartile range, CNS central nervous system, MS multisystem, LCH Langerhans cell histiocytosis, RO risk organ, SS single system, UFB unifocal bone, MFB multifocal bone
  2. aAll of these patients had concomitant diabetes insipidus
  3. bRisk organ involvement
  4. cCNS involvement was contiguous to bone lesions in one patient
  5. dPresent in the same patient